יחס חוב לטווח ארוך להון Burning Rock Biotech Ltd (BNR)

Burning Rock Biotech is expanding its liquid biopsy network by integrating DNA sequencing into the Chinese diagnostic standard. The company's strong pricing power is supported by inelastic demand for targeted therapy. Integration into hospital protocols guarantees a steady patient flow despite NMPA export restrictions. The GURU.Markets terminal displays a chart of the long-term debt-to-equity ratio, where the value 0.05 serves as the baseline indicator for asset structure stability.

For Burning Rock Biotech (BNR), which is building an NGS diagnostics ecosystem in Chinese clinics, the long-term debt-to-equity trend reflects its expansion financing strategy. This metric compares liabilities with maturities exceeding one year against the company's equity. A high value indicates significant leverage relative to net assets, which is critical for a high-tech business with substantial IT integration costs. A decline in this ratio confirms increasing financial stability and the fundamental security of the asset.